AU3850689A

AU3850689A – 11 beta-substituted progesterone analogs
– Google Patents

AU3850689A – 11 beta-substituted progesterone analogs
– Google Patents
11 beta-substituted progesterone analogs

Info

Publication number
AU3850689A

AU3850689A
AU38506/89A
AU3850689A
AU3850689A
AU 3850689 A
AU3850689 A
AU 3850689A
AU 38506/89 A
AU38506/89 A
AU 38506/89A
AU 3850689 A
AU3850689 A
AU 3850689A
AU 3850689 A
AU3850689 A
AU 3850689A
Authority
AU
Australia
Prior art keywords
norprogesterone
norpregna
dione
diene
dimethylaminophenyl
Prior art date
1988-06-23
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Application number
AU38506/89A
Other versions

AU635211B2
(en

Inventor
C. Edgar Cook
Yue-Wei Lee
Douglas Rector
Jerry R. Reel
Mansukh C. Wani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Research Triangle Institute

Original Assignee
Research Triangle Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1988-06-23
Filing date
1989-06-23
Publication date
1990-01-12

1989-06-23
Application filed by Research Triangle Institute
filed
Critical
Research Triangle Institute

1990-01-12
Publication of AU3850689A
publication
Critical
patent/AU3850689A/en

1993-03-18
Application granted
granted
Critical

1993-03-18
Publication of AU635211B2
publication
Critical
patent/AU635211B2/en

2009-06-23
Anticipated expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005

C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom

C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K31/00—Medicinal preparations containing organic active ingredients

A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P13/00—Drugs for disorders of the urinary system

A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P15/00—Drugs for genital or sexual disorders; Contraceptives

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P3/00—Drugs for disorders of the metabolism

A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P5/00—Drugs for disorders of the endocrine system

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P5/00—Drugs for disorders of the endocrine system

A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17

C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class

C07J53/002—Carbocyclic rings fused

C07J53/004—3 membered carbocyclic rings

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms

C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group

C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa

C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms

C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21

C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group

C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa

C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07J—STEROIDS

C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring

C07J71/0036—Nitrogen-containing hetero ring

C07J71/0042—Nitrogen only

C07J71/0052—Nitrogen only at position 16(17)

Abstract

A 11 beta -aryl-19-norprogesterone steroid of the formula: wherein (i) R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5 , wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl, R4 is H, CH3, F or Cl, R6 is H, (CH3)2N, CH3O, CH3CO, CH3S, CH3SO, CH3SO2, and X is O or NOCH3; or (ii) R1 and R2 taken together are a carbon-carbon bond and R3, R4, R6 and X are as defined above; or (iii) R1 and R3 taken together are -CH2- or -N=N-CH2-, R2 is H and R4, R6 and X are as defined above; or (iv) R2 and R3 taken together are =CH2 and R1 , R4, R6 and X are as defined above.

Description

Description 11β -Substituted Progesterone Analogs
Technical Field
This invention relates generally to the field of steroids, and in particular, to new 11β-substituted 19- norprogesterone analogs which possess antiprogestational or progestational activity.
Background Art
There have been many prior attempts over the past few decades to prepare steroids with antihormonal activity. These have been reasonably successful where anti-estrogens and anti-androgens are concerned. The discovery of effective antiprogestational and antiglucocorticoid steroids, however, has proved to be a formidable task for the steroid chemist. It has been generally recognized for some years, however, that antiprogestational steroids would find wide applicability in population control, while antiglucocorticoids would be extremely valuable in the treatment of, for example, Cushing’s syndrome and other conditions characterized by excessive endogenous production of cortisone. In the last decade largely through the efforts of Teutsch et al of the RousselUclaf group in France, a new series of 19-nortestosterone derivatives has been synthesized with strong affinity for the progesterone and glucocorticoid receptors and with marked antiprogestational and antiglucocorticoid activity in vivo. This important discovery revealed the existence of a pocket in the progesterone/cortisone receptors able to accommodate a large 11β-substituent on selected 19-nortestosterone derivatives. By suitable selection of such a

substituent steroids with antihormonal properties were obtained.
The pioneering studies of Teutsch et al on the synthesis of antiprogestational and antiglucocorticoid steroids is summarized in a recent review (G. Teutsch in Adrenal Steroid Antagonism. Ed. M. K. Agarwal, Walter de Gruyter and Co., Berlin, 1984. pp. 43-75) describing work leading to the discovery of RU-38,486 (I), the first steroid of this type selected for clinical development. See Figure 1. RU-38,486 or mefipristone was found to be an effective antiprogestational/contragestative agent when administered during the early stages of pregnancy (IPPF Medical Bulletin 20; No. 5, 1986). In addition to these antiprogestational properties, mefipristone had very significant antiglucocorticoid activity and was successfully used by Nieman et al (J. Clin. Endocrinology Metab. 61:536, 1985) in the treatment of Cushing’s syndrome. In common with the vast majority of steroidal hormone analogs, mefipristone additionally exhibits a range of biological properties. Thus, for example, it exhibits growth-inhibitory properties towards estrogen-insensitive T47Dco human breast cancer cells (Horwitz, Endocrinology 116:2236, 1985). Experimental evidence suggests that the metabolic products derived from mefipristone contribute to its antiprogestational and antiglucocorticoid properties (Heikinheimo et al, J. Steroid Biochem. 26:279, 1987).
There have been a number of attempts by various workers to modify the mefipristone structure in order to obtain separation of the antiprogestational activity from the antiglucocorticoid activity. Thus, the Sobering group (Steroids 44:349-519, 1984) has described analogs of mefipristone termed ZK 98.299 (II)

and ZK 98.734 (III). See Figure 1. Mefipristone is the most active antiglucocorticoid steroid relative to its antigestagenic potency while steroid (III) is the least active. Steroid (II) has an intermediate position in this respect.
Comparison of the contragestative properties of these three antiprogestational steroids (Elger et al, J. Steroid Biochem. 25:835, 1986) has not only revealed different endocrinological profiles, but has indicated the critical importance of the ratio of antiglucocorticoid to antiprogestational activity to the biological activity. It thus seems inevitable that a series of related structures possessing a gradation of antiprogestational/antiglucocorticoid properties will need to be developed in order to provide contracestative/antiglucocorticoid/antitumor products designed for specific clinical situations. Unfortunately, the art has not yet reached the stage when accurate predictions of biological properties on the basis of chemical structures can be made so that a degree of empiricism is unavoidable.
There continues to be a need for the development of new steroids with varying degrees of antiprogestational and antiglucocorticoid activities.
Disclosure of the Invention
Accordingly, one object of the present invention is to provide new steroid compounds having antiprogestational and/or antiglucocorticoidal properties.
Another object of the invention is to provide novel steroids having progestational as well as antiprogestational activity.
These and other objects which will become apparent

from the following specification have been achieved by the present 11β-aryl-19-norprogesterone compounds of the formula

wherein (i) R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5, wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl, R4 is H, CH3, F or Cl, R6 is H, (CH3)2N, CH3O, CH3CO, CH3S, CH3SO or CH3SO2 and X is O or NOCH3; or (ii) R1 and R2 taken together represent a carbon-carbon bond, and R3, R4, R6 and X are as defined above; or (iii) R1 and R3 taken together are -CH2- or -N=N-CH2-, R2 is H and R4, R6 and X are as defined above; or (iv) R2 and R3 taken together are =CH2 and R1, R4, R6 and X are as defined above.
Brief Description of the Drawings
A more complete appreciation of the invention and many of the attendant advantages thereof will be readily obtained as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein:
Figure 1 gives the structures of prior art compounds ZK 95.890, ZK 98.734 and ZK 98.299; and
Figure 2 illustrates the structures of the compounds of the present invention.

Best Mode For Carrying Out the Invention
Research in this area has dealt with 11β-aryl-19- nortestosterone analogs in which the 17β-position (or the 17α-position in the inverted compounds such as III) is substituted by a hydroxyl group. This invention provides for the first time novel 11β-aryl-19- norprogesterone analogs in which the 17β-position is substituted by an acetyl group. The resulting compounds are generally characterized by strong binding affinity to the progesterone and glucocorticoid receptors. Research in this series of structures, however, is not yet able to predict the nature of this biological activity on the basis of structure and binding affinity to the progesterone and glucocorticoid receptors. Thus in contrast to prior art which teaches that in the 11β-aryl-19-nortestosterone series, an 11β-aryl substituent, e.g. 11β-(4-N,N-dimethylaminophenyl), leads to antiprogestational activity, surprisingly in the 11β-aryl-19-norprogesterones of the present invention, strong binding to the progesterone receptor may lead to either antiprogestational or progestational activity in vivo. Thus the 17α-acetoxy structures IV (Figure 2) (R1 = OAc, R2 = R3 = H, R4 = H or CH3 , R6 = Me2N, X=0) and the 16a-ethyl structures IV (R1 = R2 = H, R3 = Et, R4 = H or CH3, R6 = Me2N, X=0) both exhibit strong binding to the progesterone receptor. The former compounds block the action of progesterone when administered in vivo, whereas the latter surprisingly show potent progestational activity in vivo. Furthermore in the 19-norprogesterone series there is not always the expected correlation between binding to the progesterone receptor and in vivo activity. Thus the Δ-16 compound IV (R1,R2 = double bond, R3 = R4 = H, R6 = Me2N, X=0) binds relatively weakly to the

progesterone receptor, but when used in vivo exhibits strong antiprogestational activity.
The 11β-substituted norprogesterone analogs of the present invention comprise compounds having structures A-C shown below.

The compounds having structure A all contain a 16β-hydrogen substituent (R2) and a 17β -acetyl substituent. The 16α substituent (R3) may be hydrogen, C1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl groups. The 17α substituent (R1) may be methyl, C2-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, hydroxyl, OC(O)CH3 (O-acetyl), or OC(O)R5, where R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl. Alternatively, the 17α- and 16α-

substituents R1 and R3 taken together are -CH2- or -N=N-CH2-.
Preferred compounds having structure A are those in which R6 is N,N-dimethylamino or acetyl. Additional preferred compounds are those in which R4 is hydrogen or methyl and R1 is acetoxy or C2-6 alkynyl groups. Specific examples of compounds having structure A are 17α-acetoxy-6α-methyl-11β-(4-N,N-dimethylaminophenyl)- 19-norpregna-4,9-diene-3,20-dione, 17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 16α-ethyl-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 16α-ethyl-6α-methyl-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 17α-ethynyl-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene3,20-dione, 11β-(4-acetylphenyl)-19-norpregna-4,9-diene-3,20-dione, 17α-acetoxy-11β-(4-acetylphenyl)-19-norpregna-4,9-diene-3,20-dione, and 17α-ethynyl-11β-(4-acetylphenyl)-19-norpregna-4,9-diene-3,20-dione.
Compounds having structure B exhibit a carboncarbon double bond between C16 and C17. R3, R4, R6 and X may be any of the groups defined above. Preferred compounds having structure B are compounds in which R6 is an N,N-dimethylamino or an acetyl group.
Additionally preferred compounds having structure B are those in which R3 is H and R4 is H or CH3. Specific examples of such compounds include 11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9,16-triene-3,20-dione and 11β-(4-acetylphenyl)-19-norpregna-4,9,16-triene-3,20-dione.
In the compounds having structure C, R2 and R3, taken together, are a =CH2 group. Preferred examples include compounds in which R1 is acetoxy or C2-8

alkynyl, R4 is hydrogen or methyl and R6 is dimethylamino or acetyl.
Preferred aryl groups for R5 in compounds A-C have the formula -C6H4-R6, in which R6 has the same meaning as defined above.
Steroids having progestational, antiprogestational and/or antiglucocorticoid activity have use in the control of fertility in humans and non-human mammals such as primates, domestic pets and farm animals, and in the treatment of ssedical conditions in animals or humans in which these activities are beneficial. Thus they may be useful in the treatment of conditions such as Cushing’s syndrome, glaucoma, endometriosis, premenstrual syndrome and cancer in addition to their use in the control of reproduction.
The compounds of the present invention may be administered by a variety of methods. Thus, those products of the invention that are active by the oral route may be administered in solutions, suspensions, emulsions, tablets, including sublingual and intrabuccal tablets, soft gelatin capsules, including solutions used in soft gelatin capsules, aqueous or oil suspensions, emulsions, pills, lozenges, troches, tablets, syrups or elixirs and the like. Products of the invention active on parenteral administration may be administered by depot injection, implants including Silastic™ and biodegradable implants, intramuscular and intravenous injections.
Compositions may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents,

coloring agents and preserving agents. Tablets containing the active ingredient in admixture with nontoxic pharmaceutically acceptable excipients which are suitable for manufacture of tablets are acceptable. These excipients may be, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of

an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethylene oxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (e.g., polyoxyethylene sorbitol mono-oleate), or a condensation product of ethylene oxide with a partial ester derived from fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan mono-oleate). The aqueous suspension may also contain one or more preservatives such as ethyl or npropyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose, aspartame or saccharin. Ophthalmic formulations, as is known in the art, will be adjusted for osmotic pressure.
Oil suspensions may be formulated by suspending the active incredient in a vegetable oil, such as arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oil suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water may be formulated from the active ingredients in admixture with a dispersing, suspending and/or wetting agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachis oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan mono-oleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan mono-oleate. The emulsion may also contain sweetening and flavoring agents.
Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
The pharmaceutical compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterallyacceptable diluent or solvent, such as a solution of 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water and Ringer’s solution, an isotonic sodium chloride. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic

mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.
The compounds of this invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable nonirritating excipient which is solid at ordinary temperatures but liquid at the rectal temperatures and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.
They may also be administered by intranasal, intraocular, intravaginal, and intrarectal routes including suppositories, insufflation, powders and aerosol formulations.
Products of the invention which are preferably administered by the topical route may be administered as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, paints, powders, and aerosols.
Products having anti-glucocorticoid activity are of particular value in pathological conditions characterized by excess endogenous glucocorticoid such as Cushing’s syndrome, hirsutism and in particular when associated with the adrenogenital syndrome, ocular conditions associated with glucocorticoid excess such as glaucoma, stress symptoms associated with excess glucocorticoid secretion and the like. Products having progestational activity are of particular value as progestational agents, ovulation inhibitors, menses regulators, contraceptive agents, agents for synchronization of fertile periods in

cattle, endometriosis, and the like. When used for contraceptive purposes, they may conveniently be admixed with estrogenic agents, such as for example as ethynylestradiol or estradiol esters. Products having anti-progestational activity are characterized by antagonizing the effects of progesterone. As such, they are of particular value in control of hormonal irregularities in the menstrual cycle and for synchronization of fertile periods in cattle.
The compounds of the invention may be used for control of fertility during the whole of the reproductive cycle. They are of particular value as postcoital contraceptives, for rendering the uterus inimical to implantation, and as «once a month» contraceptive agents. They may be used in conjunction with prostaglandins, oxytocics and the like.
A further important utility for the products of the invention lies in their ability to slow down growth of hormone-dependent cancers. Such cancers include kidney, breast, endometrial, ovarian cancers, and prostate cancer which are characterized by possessing progesterone receptors and may be expected to respond to the products of this invention. Other utilities of anti-progestational agents include treatment of fibrocystic disease of the breast. Certain cancers and in particular melanomas may respond favorably to corticoid/anticorticoid therapy.
The compounds according to the present invention may be administered to any warm-blooded mammal such as humans, domestic pets, and farm animals. Domestic pets include dogs, cats, etc. Farm animals include cows, horses, pigs, sheep, goats, etc.

The amount of active ingredient that may be combined with a carrier material to produce a single dosage form will vary depending upon the disease treated, the mammalian species, and the particular mode of administration. For example, a unit dose of the steroid may preferably contain between 0.1 milligram and 1 gram of the active ingredient. A more preferred unit dose is between 0.001 and 0.5 grams. It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs which have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those of skill in the art.
Other features of the invention will become apparent in the course of the following descriptions of exemplary embodiments which are given for illustration of the invention and are not intended to be limiting thereof.
EXAMPLES
Example 1. Synthesis of 6α-Methyl-17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione.
6α-Methyl-17α-hydroxy-pregna-1,4-diene-3,20-dione (37.72 g, 0.11 mol) was dissolved in 1 L of freshly distilled tetrahydrofuran and 400 mL of dry methanol. The solution was cooled in an ice-bath at 0°C. Sodium borohydride (3.6 g, 0.09 mol) was added in one portion and the mixture was stirred at 0-5°C for 6 h. The

reaction mixture was diluted with ice water (100 mL) and methanol was removed under reduced pressure. The resulting thick residue was partitioned between chloroform and water. The chloroform extracts (500 mL × 4) was dried over Na2SO4 (anhydrous), filtered and concentrated to give 42 g of crude 6α- methyl-17α,20β(α)- dihydroxy-pregna-1,4-dien-3-one. The product was shown to be a mixture of 20β and 20α-ol in a ratio of 85:15 based on 1H NMR analysis. For 20βol: 1H NMR (CDCI3, 60 MHz) δ 0.83 (s, 3, 18-CH3), 1.0 (d, 3, J = 6 Hz, 6-CH3), 1.18 (d, 3, J = 6 Hz, 21-CH3), 4.0 (m, 1, 20-H), 6.05 (bs, 1, 4-H), 6.15 (dd, 1, J = 12, 2 Hz, 2-H), 7.1 (d, 1, J = 12 Hz, 1-H).
Into a flame dried 2 L three-neck round bottom flask equipped with condenser and addition funnel were added tetrahydrofuran (900 mL), biphenyl (45 g, 0.29 mol) and diphenylmethane (50 mL, 0.285 mol). The mixture was heated to reflux and lithium wire (3.5 g, 0.50 mol) was added in one portion. The resulting bluish-green solution of the complex was heated at gentle reflux for 16 h. An additional 0.5 g of lithium wire was added to maintain a dark-blue color. The diol (26 g, 0.076 mol) in 170 mL of THF was then added dropwise at such a rate that the blue color persisted throughout the addition. The reaction mixture was refluxed for an additional 45 min. The excess biphenyl lithium complex was quenched carefully with methanol in an ice-bath. After dilution with water (200 mL), THF was removed under reduced pressure and the product was extracted with CHCI3 (500 mL × 3). The CHCI3 extracts were combined, dried over sodium sulfate (anhydrous), filtered and concentrated to give 118 g of the crude product. The aqueous phase was acidified with HC1 solution (10% v/v) and extracted with CHCI3 (500 mL ×

2). The CHCI3 extract was dried over Na2SO4 (anhydrous), filtered and concentrated to give 4.5 g of fairly pure 6α-methyl-19-norpregna-1,3,5(10)-triene3,17α,20β(α) -triol. The 118 g of crude reaction product was purified by SiO2 column chromatography employing a gradient system (n-hexane-CH2Cl2 to 5% acetone-CH2Cl2) to give another 11.2 g of the product: mp=175-179°C; 1H NMR (250 MHz, CDCI3) δ 0.82 (s, 3, I8-CH3), 1.17 (d, 3, J = 6.4 Hz, 21-CH3), 1.28 (d, 3, J = 6.8 Hz, 6α-CH3), 4.0 (m, 1, 20-H), 6.61 (dd, 1, J=8.5, 2.6 Hz, 2-H), 6.76 (d, 1, J = 2.6 Hz, 4-H), 7.11 (d, 1, J = 8.5 Hz, 1-H); calcd. mass for C21H30O3: 330,2095, Found: 330.2197.
Anal. Calcd for C21H30O3: C. 76.32; H. 9.15. Found: C, 76.82; H, 9.40.
The above crude phenolic product (6.5 g, 0.02 mol) was dissolved in 500 mL of methanol and treated with potassium carbonate (15.0 g, 0.10 mol) and iodomethane (20 mL, 0.32 mol). The mixture was stirred at room temperature for 48 hours. Methanol was removed under reduced pressure, the residue was diluted with water and acidified with 10% (v/v) HCl solution. The product was extracted with CHCI3 (300 mL × 3). The combined CHCI3 extract was washed with water, dried over sodium sulfate (anhydrous), filtered and concentrated to give 7.0 g of crude reaction product. SiO2 column chromatography (CH2Cl2 to 5% acetone-CH2Cl2) gave three fractions: Fraction A (4.0 g) was found to be 6α-methyl-3-methoxy-19-norpregna-1,3,5(10)-triene-17α,20β(α)- diol. Fraction B (0.74 g) was found to be its 20α-hydroxy isomer and Fraction C (0.54 g) was the recovered starting phenol. For the 20β-ol: mp=145-147°C; 1H NMR (250 MHz, CDCI3) δ 0.82 (s, 3, I8-CH3), 1.20 (d, 3, J = 6.3 Hz, 2I-CH3), 1.30 (d, 3, J = 7.0

Hz, 6α-CH3), 2.79 (s, 3, OCH3 , 4.06 (m, 1, 20-H), 6.73 (dd, 1, J = 8.7, 2.7 Hz, 2-H), 6.82 (d, 1, J = 2.7 Hz, 4-H), 7.20 (d, 1, J = 8.7 Hz, 1-H); Calcd mass for C22H32O3: 344.2355. Found 344.2355. Anal. Calcd for C22H32O3: C, 77.16; H, 8.83. Found: C, 77.14: H, 8.88. For 20α-ol: mp=150-151°C; 1H NMR (250 MHz, CDCI3) – 0.75 (s, 3, 18-CH3), 1.22 (d, 3, J = 6.4 Hz, 2I-CH3), 1.30 (d, 3, J = 6.9 Hz, 6α-CH3), 3.79 (s, 3, OCH3), 3.85 (m, 1, 20-H), 6.70 (dd, J = 8.7, 2.7 Hz, 2- H), 6.82 (d, 1, J = 2.7 Hz, 4-H), 7.20 (d. 1. J = 8.6 Hz, 1-H).
Liquid ammonia (35 mL) was condensed into a flame dried three-neck round bottom flask equipped with a Dewar condenser and an additional funnel. Lithium wire (150 mg, 21.6 mmol) was added and the resulting bluish solution of the Li/NH3 complex solution was stirred at -78°C for 1 hour. The above methyl ether (380 mg. 1.11 mmol) in 2.0 mL of dry THF and 1.0 mL of t-butanol was added dropwise. The blue color persisted throughout the addition. The resulting mixture was stirred at -78°C for an additional 45 minutes and quenched carefully with methanol until the blue color faded. Excess ammonia was evaporated under a slow stream of nitrogen. The residue was diluted with water and neutralized with 10% (v/v) HCl solution. The product was extracted with CHCI3 (50 mL × 3). The CHCI3 extract was dried over Na2SO4 (anhydrous), filtered and concentrated to give 380 mg of crude 6α-methyl-3methoxy-19-norpregna-2,5(10)-diene-17α,20β-diol. 1H NMR (60 MHz) δ 0.80 (s, 3, I8-CH3), 1.0 (d, 3, J = 6.4 Hz, 6α-CH3), 1.2 (d, J = 6 Hz, 21-CH3), 3.5 (s, 3, 3-OCH3), 4.0 (m, 1, 20-H), 4.6 (bs, 1, 2-h).
Without further purification the crude Birch reduction product was dissolved in 40 mL of methanol

and treated with oxalic acid (250 mg in 1.5 mL of H2O). The mixture was stirred at room temperature for 5 hours and then solvent removed under pressure and the product extracted with CHCl3 (50 mL × 3). The CHCI3 extract was dried over Na2SO4 (anhydrous), filtered and concentrated to give 350 mg of the crude hydrolyzed product. Column chromatography (SiO2; gradient from CH2Cl2 to 5% acetone CH2Cl2) gave 120 mg of 6α-methyl-17α,20β-dihydroxy-19-norpregn-5(10)-en-3-one: 1H NMR (250 MHz, CDCI3) δ 0.82 (s, 3, 18-CH3), 0.99 (d, 3, J = 6.9 Hz, 6α-CH3, 1.18 (d, 3, J = 6.2 Hz, 21-CH3), 2.4 (bs, 2, 4-H), 4.0 (m, 1, 20-H).
Purified 6α-methyl-17α,20β-dihydroxy-19-norpregna5(10)-en-3-one (8.31 g, 0.025 mol) in 450 mL of dry pyridine was cooled in an ice bath and treated with pyridinium hydrobromide perbromide (9.30 g, 0.028 mol). After the mixture was stirred at room temperature for 24 hours, it was poured into ice-cold sodium sulfite solution (500 mL, 10% w/v) and extracted with CHCI3 (400 mL × 3). The CHCI3 extract was washed with dilute NaHCO3 solution (5% w/v), dried over Na2SO4 (anhydrous), filtered and concentrated to give 8.5 g of crude reaction product. Column chromatography (SiO2; gradient from CH2Cl2 to 5% acetone in CH2Cl2) gave 5.8 g of 6α-methyl-17α,20β-dihydroxy-19-norpregna-4,9-dien-3-one: mp=201-203°C; 1H NMR (250 MHz, CDCI3), δ 0.97
(s, 3, 18-CH3); 1.13 (d, J = 6.5 Hz, 6α-CH3), 1.19 (d, 3, J = 6.2 Hz, 21-CH3), 4.08 (m, 1, 20-H), 5.8 (bs, 1, 4-H), IR (CHCI3) 3550-3400; (-OH), 1665 (conjugated 3-C=O) cm-1; DV (MeOH) λmax 305 nm; MS Calcd mass for
C21H30O3 330.2195; Found 330.2194; Anal. Calcd for C21H30O3; C, 76.33; H, 9.15. Found: C, 76.35; H, 9.17.
To a stirred solution of CH2Cl2 (150 ml) and

oxalyl chloride (4.5 mL, 0.050 mol) was added DMSO (9.0 mL, 0.12 mol) at -60°C in a dry ice-CHCl3 bath. The mixture was stirred for 5 min and the above compound (5.7 g, 0.017 mol) in 60 mL of methylene chloride was added during 5 min; stirring was continued for an additional 30 min. Triethylamine (25 mL, 0.175 mol) was added and the reaction mixture was stirred for 15 min and then allowed to warm briefly to room temperature. Water (150 mL) was then added and the aqueous layer was reextracted with CH2Cl2 (300 mL × 2). The organic layers were combined, washed with saturated NaCl solution, dried, filtered and concentrated to give 5.8 g of crude reaction product. Column chromatography (SiO2; CH2Cl2 → 10% acetone in CH2Cl2) provided 5.1 g of 6α-methyl-17α-hydroxy-19-norpregna-4,9(10)-diene-3,20-dione. Recrystallization from MeOH gave white crystals: mp=230-232°C; 1H NMR (CDCl3, 60 MHz) δ 0.78 (s, 3, 18-CH3), 1.10 (d, 3, J = 6.5 Hz, 6α-CH3), 2.25 (s, 3, 21-CH3), 5.85 (bs, 1, 4- H), IR (CHCI3) 1700 (20-C=0), 1665 (conjugated 3-C=0) cm-1; UV (MeOH) λmax 305 nm; Calcd mass for C21H28O3: 328.2038. Found: 328.2038; Anal. Calcd for C21H28O3: C, 76.79; H, 8.59. Found: C, 76.87; H, 8.64. To a solution of the above dione (5.8 g, 0.018 mol) in 450 mL of dry benzene was added ethylene glycol (24.0 mL) and p-toluenesulfonic acid (500 mg). The mixture was heated to reflux and a total of 150 mL of benzene was distilled off over a period of 3 h. The reaction mixture was poured over ice water and extracted with ethyl acetate (300 mL × 3). The organic phase was washed with water, dried over sodium sulfate (anhydrous), filtered and concentrated. The crude residue was chromatographed over SiO2 (100% CH2Cl2 → 2%

acetone-CH2Cl2) to give 4.6 g of 6α-methyl-3,3,20,20-bis-(ethylenedioxy)-19-norpregna-5 (10 ),9(11)-dien-17α-ol together with 1.0 g of 6β-methyl-3,3,20,20-bis-(ethylenedioxy)-19-norpregna-5(10),9(11)-dien-17α-ol. For the 6α-methyl-3,20-diketal: mp=157-158°C; 1H NMR (CDCl3, 250 MHz) δ 0;78 (s, 3, 18-CH3); 0.99 (d, 3, J = 6.8 Hz, 6α-CH3), 1.37 (S, 3, 21-CH3), 3.98 (m, 8, 3,3,20,20-bisketals), 5.57 (bs, 1, 11-H), Calcd mass for C25H36O5: 416.2563. Found 416.2564; Anal. Calcd for C25H36O5: C, 72.08; H, 8.71. Found: C, 72.14; H, 8.75.
To a solution of the above bisketal (3.2 g, 7.7 mmol) in 75 mL of methylene chloride/hexane (1:3) was added m-chloroperbenzoic acid (1.62 g, 80%) at 0°C. The mixture was stirred at 0°C for 10 min and then diluted with sodium bicarbonate solution (25 mL, 5% w/v). The aqueous phase was extracted with CH2Cl2 (50 mL × 22). The combined organic phase was washed with saturated sodium chloride solution, dried over sodium sulfate (anhydrous), filtered and concentrated to give 3.4 g of crude epoxides which consisted mainly of 5α ,10α-epoxide as revealed by TLC and 1H NMR analyses: 1H NMR (CDCI3, 60 MHz) δ 0.75 (s, 3, 18- CH3), 0.95 (d, 3, J = 6.0 Hz, 6α-CH3), 1.30 (s, 3, 21- CH3), 3.8-4.0 (m, 8, 3, 20-ketals), 5.8 (m, 1, 11-H).
The crude epoxide (3.4 g, 7.43 mmol) in dry tetrahydrofuran (25 mL) was added dropwise to a Grignard solution of p-N,N-dimethylaminophenylmagnesium bromide in the presence of dimethylsulfide cuprous bromide complex (1.8 g. 8.6 mmol). The Grignard mixture was prepared from p-bromo-N,N-dimethylaniline (14.0 g, 70 mmol) and magnesium (1.4 g, 57 mmol) in 150 mL of freshly distilled tetrahydrofuran. After the reaction mixture was stirred at room temperature and

under nitrogen for 30 min., it was poured into saturated ammonium chloride solution (350 mL) and stirred for 20 min. Extraction with ethyl acetate (500 mL × 3) and evaporation of the solvent gave a bluish residue which was first purified by Al2O3 column chromatography to provide 3.7 g of semi-purified product. Repeated silica gel column chromatography yielded 1.95 g of 6α-methyl-11β-(4-N,N- dimethylaminophenyl)-3,3,20,20-bis(ethylenedioxy)-19- norpregn-9-en-5α-ol. Recrystallization from
MeOH/CH2Cl2 gave 1.2 g of needles: mp=227-228°C; 1H NMR (250 MHz, CDCI3) δ 0.46 (s, 3, 18-CH3), 1.06 (d, 3, J = 6.6 Hz, 6α-CH3), 1.38 (s, 3, 2I-CH3), 2.89 (s, 6, -N(CH3)2), 3.8-4.0 (m, 8, 3, 20-diethylene ketal-H), 4.19 (d, 1 , J = 6.2 Hz, 11α-H), 6.62 (d, 2, J = 8.8 Hz, aromatic H ortho to -N(CH3)2), 7.06 (d, 2, J = 8.8 Hz, aromatic-H, meta to -N(CH3)2); Calcd for C33H47O6N: C, 71.58; H, 8.56; N, 2.53. Found: C, 71.70; H, 8.59; N, 2.51. Phosphoric acid (85%, 6.5 mL) was added dropwise into acetic anhydride (18 mL) in an ice-bath. The mixture was stirred at 5-10°C for 30 min and diluted with acetic acid (20 mL). The resulting mixture was warmed to room temperature and stirred for 1 hour. The above 17α-hydroxy-3,20-diketal (680 mg, 1.52 mmol) in dry dioxane (4.0 mL) was added to the phosphoric acid/acetic anhydride/acetic acid solution (8.0 mL). The mixture turned immediately into a dark-blue solution. The progress of the acetylation was carefully monitored with reverse phase-HPLC analyses. The reaction was stirred at room temperature for 8 hours and diluted with water followed by neutralization with sodium bicarbonate solution (5% w/v). The product was extracted with ethyl acetate (200 mL × 3). The

organic phase was dried over sodium sulfate (anhydrous), filtered and concentrated to give 750 mg of crude reaction product which was purified by AI2O3 column chromatography followed by repeated reversephase column chromatography employing a RP-C8 (Lobar size B) column and 20% H2O in MeOH as the eluting solvent system. Each individual fraction collected was monitored by an analytical Zorbax-ODS (4.5 mm x 25 cm) column with the same solvent system. The fractions showing greater than 95% purity were combined and solvent was evaporated. Further recrystallization from MeOH/H2O provided 110 mg of white crystals of 6amethyl-17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione. The major contaminant found both in the mother liquor and in the overlapping fractions was the 6β-methyl isomer. For the 6α-methyl isomer: mp=189-190.5°C; 1H NMR (250 MHz, CDCI3) δ 0.35 (s, 3, 18-CH3), 1.24 (d, 3, J = 6.5 Hz, 6α-CH3), 2.09 (s, 3, 17o-OAc), 2.12 (s, 3, 21-CH3), 2.9 (s, 6, -N(CH3)2), 4.40 (d, 1, J = 7.2 Hz, 11α-H), 5.89 (bs, 1, 4-H) , 6.62 (d, 2, J = 8.8 Hz aromatic-H, ortho to -N(CH3)2), 6.96 (d, 2, J = 8.8 Hz aromatic-H, meta to -N(CH3)2); Calcd mass for C31H3904N: 489.2879. Found 489.2878; IR (CHCI3), 1730 (17α-C=0), 1720 (20-C=0), 1655 (conjugated 3-C=0) cm-1; UV (MeOH) λmax 302 nm (dienone), 264 nm (aromatic group); Anal, calcd for
C31H39O4N: C, 76.04; H, 8.02; N, 2.86. Found: C, 76.10; H, 8.03; N, 2.84.
Example 2. Synthesis of 17α-Acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione
3-Methoxy-19-norpregna-1,3,5(10),17(20)-tetraene (Krubiner and Oliveto, 1966) (1.0 g, 0.0034 mol) in dry pyridine (15 mL) was treated with osmium tetroxide

(1.0 g). The resulting dark brown solution was stirred at room temperature for 2 hours and a solution of sodium bisulfite (1.8 g in 30 mL H2O) and pyridine (20 mL) was added and the mixture was stirred for an additional 15 min.
The product was extracted with ethyl acetate and the combined organic phase was washed with water, dried over sodium sulfate (anhydrous), filtered and concentrated. Flash chromatography (SiO2; 10% acetone in CH2Cl2) provided 0.82 g of 3-methoxy-19-norpregna- 1,3,5(10)-triene-17α,20α-diol: 1H NMR (CDCI3, 250 mHz) δ 0.76 (s, 3, 18-CH3), 1.23 (d, 3, J = 6.3 Hz, 21-H), 3.77 (s, 3, OMe), 3.87 (q, 1, J = 6.3 Hz, 20-H), 6.62 (d, 1, J = 2.8 Hz. 4-H), 6.70 (dd, 1, J = 8.5. 2.8 Hz, 2-H), 7.20 (d, 1, J = 8.5 Hz, 1-H).
By reduction with lithium in ammonia followed by oxalic acid treatment as described in Example 1, the above methyl ether (760 mg) was converted to 3-methoxy19-norpregna-2,5(10)-diene-17α,20α-diol and thence to 17α,20α-dihydroxy-19-nor-5(10)-pregnen-3-one. 1H NMR (90 MHz, CDCI3), δ 0.80 (s, 3, 48-CH3), 1.2 (d, 3, J = 6.5 Hz. 21-H), 2.4 (bs, 2, 4-H), 4.0 (m, 1, 20-H).
Pyridinium hydrobromide perbromide (1.5 mmol) as in Example 1, converted this compound to 230 mg of 17α,20(α)-dihydroxy-19-norpregna-4,9-dien-3-one. 1H NMR (CDCI3, 90 MHz) δ 0.95 (S, 3, 18-CH3), 1.15 (d, 3, J = 6.5 Hz, 21-H), 4.1 (m, 1, 20-H), 5.7 (s, 1, 4-H).
Oxidation of the above diol (210 mg) with oxalyl chloride and dimethylsulfoxide as in Example 1 gave 17α-hydroxy-19-norpregna-4,9-diene-3,20-dione: 1H NMR (CDCl3, 90 MHz) δ 0.87 (s, 3, 18-CH3), 2.25 (s, 3, 21-H), 5.70 (bs, 1, 4-H); IR (CHCI3) 1700 (20-C=0), 1665 (conjugated 3-C=0) cm-1. This compound was converted

to 190 mg of 3,3,20, 20-bis-(ethylenedioxy)-19-norpregna-5(10),9(11)-dien-17α-ol by the procedure described in Example 1: % NMR (CDCI3, 90 MHz) δ 1.35
(s, 3, 21-H), 0.80 (s, 3, 18-CH3), 3.98 (m, 8, 3,20-ketals), 5.6 (bs, 1, 11-H).
The above bisketal (175 mg) was epoxidized with meta-chloroperbenzoic acid by the procedure of Example 1 to yield crude 5α,10α-epoxy-3,3,20,20-bis-(ethylenedioxy)-19-norpregn-9(11)-en-17α-ol (25) which underwent copper catalyzed Grignard addition as in Example 1 to provide 100 mg of 3,3,20,20-bis(ethylenedioxy)-11β-(4,N,N-dimethylaminophenyl)-19-norpregn-9-ene-5α,17α-diol: 1H NMR (CDCl3, 90 MHz) δ0.46 (s, 3, 18-CH3), 1.38 (s, 3, 21-H), 2.89 (s, 6, -N(CH3)2), 3.8 (m, 8, 3,20-ketals), 4.78 (bt, 1, llαH), 6.6-7.1 (m, 4, aromatic-H).
Treatment of this compound with acetic anhydride/phosphoric acid as described in Example 1 yielded 17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione which was recrystallized from MeOH/H2O to give 25 mg of the final product: mp=118-121°C; 1H NMR (CDCl3, 250 MHz) δ 0.36 (s, 3, 18-CH3), 2.09 (s, 3, 17α-OAc), 2.13 (s, 3, 21-CH3), 2.9 (s, 6, -N(CH3)2), 4.39 (d, 1 J = 7.0 Hz, llα-H), 5.7.7 (s, 1, 4-H), 6.6 (d, 2, J = 8.6 Hz, aromatic ortho-H to
-N(CH3)2), 6.9 (d, 2, J = 8.6 Hz, aromatic meta-H to
N(CH3)2; IR (CHCI3) 1730 (20-C=O), 1660 (3-conjugated
C=0) cm-1; UV (MeOH), λmax , 261 nm; Anal. Calcd. for
C30H37NO4: C, 75.76; H, 7.84; N, 2.94. Found: C, 74.18; H, 7.75; N, 2.81.
Example 3. Synthesis of 6α-Methyl-16α-ethyl-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20- dione.

6α-Methyl-3-methoxy-19-norpregna-1,3,5(10)-triene17α,20β-diol (900 mg, 2.6 mmol) in 30 mL of THF was treated with H5IO6 solution (400 mg in 10 mL THF). The reaction mixture was stirred at room temperature for 45 min and filtered through a short neutral alumina column. The filtrate and THF washings were combined and concentrated to give 750 mg of product. Recrystallization from methanol gave 450 mg of 3- methoxy-6α-methyl-1,3,5(10)estratrien-17-one: mp=108- 109°C; 1H NMR (CDCI3, 90 MHz) δ 0.88 (s, 3, 18-CH3),
1.3 (d, 3, J = 6.5 Hz, 6α-Me), 3.75 (s, 3, 3-OMe), 6.8- 7.2 (m, 3, aromatic H); IR (CHCl3) 1740 cm-1 (17-C=0); Anal, calcd for C20H26O2: C, 80.5; H, 8.78. Found:
C, 80.59; H. 8.80. A solution of the above 6α-methylestrone-3-methyl ether (5.2 g. 0.017 mol) in dry toluene was added rapidly to a stirred solution of ethylidenetriphenyiphosphorane freshly prepared from
6.3 g of NaH in 100 mL of DMSO and ethyltriphenylphosphonium iodide (54.8 g, 0.13 mol). The reaction mixture was stirred at 60°C for 18 hours and was then poured over ice. The product was taken up with ethyl acetate. The combined organic phase was dried over sodium sulfate, filtered, and concentrated to give 8.5 g of crude product which was purified by SiO2 column chromatography (hexane – CH2Cl2, 1:1) to give 4.8 g of 3-methoxy-6α-methyl-19-norpregna-1,3,5(10),17(20)-tetraene. 1H NMR (CDCI3, 90 MHz) δ 0.89 (s, 3, 18-CH3): 1.3 (d, 3, J = 6.5 Hz, 6α- CH3), 1.6 (d, 3, J = 7 Hz, 21-H), 3.8 (s, 3, OMe), 5.1 (m, 1, 20-H), 6.8-7.2 (m, 3, aromatic-H); IR (CHCI3), no C=0.
A solution of the above olefin (500 mg, 1.61 mmol) and hematoporphyrin (22 mg) in 20 mL of pyridine was

treated with a fine stream of oxygen while being illuminated with a 22 W fluorescent lamp. After 4.5 h, 5 mL of acetic anhydride was added and the reaction mixture was allowed to stand at room temperature for 45 min and was then heated at 60°C for additional 30 min. After dilution with water, the product was extracted with methylene chloride and the organic phase washed thoroughly with 1N HCl and then with 5% sodium bicarbonate solution. After drying, the methylene chloride solution was slurried with 15 g of neutral alumina oxide and filtered. The concentrated crude reaction product was further purified by SiO2 column chromatography (15% acetone in CH2Cl2) to provide 350 mg of 3-methoxy-6α-methyl-19-norpregna-1,3,5(10),16-tetraen-20-one: mp=106-109°C; 4H NMR (CDCI3, 90 MHz), δ 0.90 (s, 3, 18-CH3), 1.29 (d, 3, J = 6.5 Hz, 6α-CH3), 2.23 (s, 3, 21-H), 3.75 (s, 3, OMe) , 6.7 (m, 3, 2, 4 & 16-H), 7.15 (d, 1, J = 7 Hz, 1-H): IR (CHCI3) 1670 (conjugated 20-C=0) cm-1 Ethylmagnesium bromide (12.5 mL, 25 mmol) 2 M in THF was added to a suspension of Me2S·CuBr complex (2.4 g, 0.0177 mol) in 80 mL of THF at 0°C under N2. The resulting blue solution of the complex was stirred at 0°C for 20 min and then was added to a cold solution of the above tetraene (1.5 g, 0.0046 mol) in 40 mL of THF. The reaction mixture was stirred for 30 min at 0°C and then diluted with 1 N HCl solution (15 mL). The product was extracted with ethyl acetate. The organic phase was dried, filtered and concentrated to give 2.0 g of crude reaction product. Column chromatography (SiO2; 2% acetone in CH2Cl2) provided 1.5 g of 3-methoxy-6α-methyl-16α-ethyl-19-norpregna-1,3,5(10)-trien-20-one; 1H NMR (CDCI3, 250 MHz) δ 7.18 (d, 1, J = 8.6 Hz, 1-H), 6.75 (m, 2, 2 & 4-H), 3.78 (s,

3 , OMe ) , 2 . 15 ( s , 3 , 21-H) , 1 . 30 ( d, 3 , J = 6 . 8 Hz , 6α- CH3 ) , 0. 85 ( t , 3 , J = 7 Hz , 16-CH2CH3 ) , 0. 65 ( s , 3 , 18- CH3 ) ; IR (CHCl3 ) 1702 ( 20-C=0) cm-1.
The above 20-keto compound (7.0 g, 0.020 mol) in THF (250 mL) and methanol (80 mL) was cooled to 0°C in an ice bath and treated with sodium borohydride (1.0 g, 0.027 mol). The mixture was stirred at 0°C for 6.5 hours and was then poured carefully into crushed ice. The product was extracted with ethyl acetate. The organic extract was dried, filtered and concentrated to give 7.3 g of crude product which was purified by Si02 column chromatography (2% acetone in CH2Cl2) to provide 6.8 g of 3-methoxy-6α-methyl-16α-ethyl-19-norpregna- 1,3,5(10)-trien-20β(α)-ol: 1H NMR (CDCI3, 250 MHz) δ 0.82 (s, 3, 18-CH3), 0.90 (t, 3, J = 7.2 Hz, 16-CH2CH3), 1.22 (d, 3, J = 6.3 Hz, 6α-CH3), 1.30 (d, 3, J = 6.8 Hz, 21-H), 2.9 (m, 1, 20-H), 3.78 (s, 3, 3OMe), 6.7 (dd, 1, J = 8.5, 2.7 Hz, 2-H), 6.8 (d, 1, J = 2.7 Hz, 4-H), 7.20 (d, 1, J = 8.5 Hz, 1-H). By the lithium in liquid ammonia procedure of Example 1, the above steroid (4.0 g. 0.0113 mol) was converted to 3.95 g of crude 3-methoxy-6α-methyl-16α-ethyl-19-norpregna-2,5(10)-dien-20β(α)-ol which upon treatment with oxalic acid by the procedure in Example 1 provided 2.85 g of 6α-methyl-16α-ethyl-20β(α)-hydroxy-19-nor-5(10)-pregnen-3-one: 1H NMR (CDCI3, 250 MHz) δ 0.82 (s, 3, 18-CH3), 0.89 (t, 3, J = 7.0 Hz, 16-CH2CH3), 1.0 (d, 3, J = 6.9 Hz, 6α-CH3), 1.20 (d, 3, J = 6.2 Hz, 21-H), 3.8 (m, 1, 20-H). Treatment of the latter (220 mg) with pyridinium hydrobromide perbromide by the procedure of Example 1 provided 22 mg of 20α-isomer and 150 mg of 20β-isomer of 20-hydroxy-6α-methyl-16α-ethyl-19-norpregna-4,9-dien-3-one. For 20β-ol; 1H NMR (CDCl3, 250 MHz) δ 0.88

(t, 3, J = 7.0 Hz, 16-CH2CH3), 0.97 (s, 3, 18-CH3), 1.15 (d, 3, J =6.5 Hz, 6α-CH3), 1.22 (d, 3, J = 6.2 Hz, 21-H), 3.8 (m, 1, 20-H), 5.8 (s, 1, 4-H) : IR (CHCI3) 3400 (-OH), 1660 (conjugated 3-C=0), cm-1; Anal. Calcd. for C23H34O2: C, 80.65; H. 10.00. Found: C, 79.36; H, 9.95. For 20α-ol: 1H NMR (CDCl3, 250 MHz), δ 0.86 (s, 3, I8-CH3), 0.91 (t, 3, J = 7.2 Hz, 16CH2CH3), 1.15 (d, 3, J = 6.5 Hz, 6α-CH3), 1.26 (d, 3, J = 6.2 Hz, 21-H), 3.8 (m, 1, 20-H), 5.8 (s, 1, 4-H). Oxidation of the above 20-ol (230 mg) with oxalyl chloride and dimethylsulfoxide by the procedure in Example 1 afforded 165 mg of 6α-methyl-16α-ethyl-19-norpregna-4,g-diene-3,20-dione: mp=118-119°C; 1H NMR (CDCI3, 250 MHz), δ 0.80 (s, 3, 18-CH3), 0.82 (t, 3, J =7.1 Hz, 16-CH2CH3), 1.15 (d, 3, 6.5 Hz, 6α-CH3), 2.15 (s, 3, 21-H), 5.8 (s, 1, 4-H) : IR (CHCI3), 1705 (20-C=0), 1665 (conjugated 3-C=0) cm-1; Anal, calcd. for C23H32O2: C, 81.13; H, 9.47. Found: C, 81.01; H, 9.48. This latter compound (410 mg, 1.2 mmol) was converted with ethylene glycol and p-toluenesulfonic acid by the procedure of Example 1 to 3,3,20,20-bis-(ethylenedioxy)-6α-methyl-16α-ethyl-19-norpregna5(10),g(ll)-diene (320 mg): 1H NMR (CDCl3, 90 MHz) δ 0.80 (s, 3, 18-CH3), 0.85 (t, 3, J = 7 Hz, 16- CH2CH3), 1.1 (d, 3, J = 6.5 Hz, 6α-CH3), 2.1 (s, 3, 21-H), 3.8-4.0 (m, 8, 3,20-ketals), 5.5 (bs, 1, 11-H).
Epoxidation of the bisketal (305 mg. 0.71 mmol) with m-chloroperbenzoic acid (220 mg, 1.28 mmol) followed by the copper catalyzed Grignard addition procedure of Example 1 gave 1.2 g of dark blue residue containing 3 ,3,20,20-(ethylenedioxy)-6α-methyl-16α-ethyl-11β-(4-N,N-dimethylaminophenyl)-19-nor-9-pregnen-5α-ol.

Without further purification, the above material was treated with 70% aqueous acetic acid and then heated at 50°C for 40 min. The reaction mixture was poured into ice water and neutralized with 10% (w/v) NaHCO3 solution. The product was extracted with
CH2Cl2, dried over sodium sulfate (anhydrous), filtered and concentrated to give 240 mg of dark blue solid. Column chromatography (SiO2; 5% acetone-CH2Cl2 ) provided 42 mg of a single spot (TLC) material. An HPLC analysis (Zorbax-ODS 4.6 mm × 25 cm. 15% H2O in MeOH) showed that the product consisted of 6α and 6β- methyl isomers in an approximate ratio of 2:1. A preparative Rp-C18 column chromatography (20% H2O in MeOH) provided 7.0 mg of 6α-methyl-16α-ethyl-11β-(4- N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and 2.5 mg of 6β-methyl-16α-ethyl-llβ-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, together with 15 mg of unresolved mixture. For 6αmethyl compound: mp=95-98°C; 1H NMR (CDCI3, 250 MHz) δ 0.36 (s, 3, 18-CH3), 0.82 (t, 3, J = 7.2 Hz, 16-CH2CH3), 1.22 (d, 3, J = 6.5 Hz, 6α-CH3), 2.16 (s, 3, 21-H), 2.9 (s, 6, N(CH3)2), 4.32 (d, 1, J = 6.7 Hz, 11α-H), 5.88 (S, 1, 4-H), 6.6 (d, 2, J = 8.7 Hz, aromatic-H ortho to N(CH3)2), 6.98 (d, 2, J = 8.7 Hz, aromatic-H meta to N(CH3)2). IR (CHCI3) 1702 (20-C=0), 1660 (conjugated 3-C=0) cm1; UV (MeOH) λmax 301, 260 nm; MS calcd. 459.3137. Found: 459.3141; Anal, calcd. for C31H41NO2; C, 80.99; H, 8.92; N, 3.04. Found: C, 80.18; H, 9.02; N, 2.94. For the 6β-methyl isomer: 1H NMR (CDCI3, 250
MHz) δ 0.39 (s, 3, 18-CH3), 0.82 (t, 3, J = 7.2 Hz, 16-CH2CH3), 1.28 (d, 3, J = 7.1 Hz, 6β-CH3), 2.17 (s, 3, 21-H), 2.9 (s, 6, N(CH3)2), 4.33 (d, 1, J = 6.7 Hz, 11α-H), 5.78 (s, 1, 4-H), 6.6 (d, 2, J = 8.7 Hz, aromatic-H ortho to N(CH3)2), 6.98 (d, 2, J = 8.7 Hz,

aromatic-H meta to -N(CH3)2).
Example 4. Synthesis of 16α-Ethyl-11β-(4-N,N-dimethylaminophenyl)-ig-norpregna-4,g-diene-3,20-dione.
A solution of sodium hydride (0.27 g, 11.3 mmol) in anhydrous dimethyl sulfoxide (15 mL) was heated at 75°C for 1 hour. The reaction mixture was then cooled to room temperature and a solution of ethyl triphenylphosphonium iodide (4.6 g, 11.3 mmol) in dimethyl sulfoxide (10 mL) was slowly added. After stirring at room temperature for 15 min, a solution of 3,3-ethylenedioxy-11β-(4-N,N-dimethylaminophenyl-5α-hydroxyestr-9-en-17-one (prepared according to Cook et al, U.S. patent application serial no. 908,288 (1.0 g, 2.2 mmol) in anhydrous toluene (25 mL) was added dropwise, and the reaction mixture was subsequently heated at 80°C for 2 hours. The solution was cautiously poured into ice water (250 mL) and extracted with methylene chloride (3 × 150 mL). The combined extracts were washed with water (2 × 50 mL) and brine. Removal of the dried (Na2SO4) solvent in vacuo yielded the crude product which was purified by elution from silica gel (50 g) using 1:1 ether-hexane containing 0.1% Et3N to give 0.69 g (68%) of 3,3-ethylenedioxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-9,17(20)-dien-5α-ol: mp=174-177°C; IR
(CHCl3) 3600 cm-1; 1H NMR (250 MHz, CDCl3) δ 0.56 (s, 3, 18-H), 2.91 (s, 6, NMe2), 3.98 (m, 4, OCH2CH2O), 4.19 (m, s, 11-H), 4.29 (s, 1, 5-OH), 5.08 (m, 1, 20-H), 6.50 (d, J = g Hz, 2, ArH ortho to NMe2), 7.0g (d, J = g Hz, 2, ArH meta to NMe2). Mass spectrum: m/z required for C30H41NO3: 463.3086. Found: 463.3085. Anal. Calcd for C30H41NO3: C, 77.71; H, 8.91; N, 3.02. Found: C, 77.45; H, 8.93; N, 2.95.

Oxygen gas was slowly bubbled through a solution of the above olefin (0.33 g. 0.7 mmol) and hematoporphyrin (15 mg) in pyridine (7 mL), while the solution was irradiated with a fluorescent lamp (25 w) placed 7 cm from the reaction flask. After 3 days, the bubbling of oxygen was discontinued. To this reaction mixture was then added acetic anhydride (3 mL), and the solution stirred at room temperature for 2 hours. The solvents were then removed in vacuo at room temperature, and the residue eluted from silica gel (50 g) using 2% acetone in methylene chloride containing 0.1% Et3N to give 140 mg of unchanged starting material. Continued elution with 4% acetone in methylene chloride containing 0.1% Et3N yielded 3,3- ethylenedioxy-11β-(4-N,N-dimethylaminophenyl)-5α- hydroxy-19-norpregna-9,16-dien-20-one (55 mg, 30% based on recovered starting material) as crystals; mp=225228°C; IR (CHC13) 3600, 1675 cm-1; 1H NMR (250 MHz, CDCI3) δ 0.59 (s, 3, 18-H), 2.24 (s, 3, 21-H), 2.90 (s, 6, NMe2), 3.98 (m, 4, OCH2CH2O), 4.18 (m, 1, 11-H), 4.37 (s, 1, 5-OH), 6.65 (d, J = 9 Hz, 2, ArH ortho to NMe2), 6.67 (apparent s, 1, 16-H), 7.10 (d, J = 9 Hz, 1, ArH meta to NMe2). Mass spectrum: m/z required for C30H39NO4 (M+-18); 459.2773. Found: 459.2774. Anal. Calcd for C30H39NO4 · 1/4 H2O: C, 74.88; H, 8.24; N, 2.90. Found: C, 74.72; H, 8.31; N, 2.86.
To a cold (0°C), stirred suspension of copper bromide-dimethyl sulfide complex (120 mg, 0.58 mmol) in anhydrous tetrahydrofuran (1 mL) was slowly added 0.4 mL (2.0 molar, 0.8 mmol) of ethylmagnesium bromide in tetrahydrofuran. After stirring at 0° for 0.5 h, the Grignard complex was rapidly added to a cold (0°C), stirred solution of the above unsaturated ketone (16 mg, 0.034 mmol) in tetrahydrofuran (0.5 mL). After

stirring at 0°C for 2 h, the reaction mixture was added dropwise to a cold (0°C), rapidly stirred solution of 3
N hydrochloric acid (1 mL). After stirring at room temperature for 2 h, the mixture was poured into a saturated solution of sodium bicarbonate (10 mL) and extracted with ethyl acetate (3 × 25 mL) . The combined extracts were washed with water (2 × 50 mL) and brine. Removal of the dried (Na2SO4) solvent in vacuo yielded the crude product which was purified by elution from a reverse phase C-8 column (size B, E. M. Merck) using 85% aqueous methanol to yield 11 mg (80%) of
16α-ethyl-11β-(4-N,N-dimethylaminophenyl)-19-norpregna- 4,9-diene-3,20-dione as off-white crystals; mp=168-171°C; IR (CHCl3) 1720, 1680 cm-1; 1H NMR (250 MHz, CDCl3) δ 0.36 (s, 3, 18-H), 0.82 (t, 3, J = 7 Hz,
CH2CH3), 2.16 (s, 3, 21-H), 2.91 (s, 6, NMe2), 4.32 (m,
1, 11-H), 5.76 (s, 1, 4-H) , 6.64 (d, J = 9 Hz, 2, ArH ortho to NMe2), 6.98 (d, J = 9 Hz, 2, ArH meta to
NMe2). Mass spectrum: m/z required for C30H39NO2; 445.2981. Found: 445.2977. Anal. Calcd for
C30H39NO2: C, 80.85 H, 8.82; N, 3.14. Found: C, 80.75; H, 8.85; N, 3.09.
Example 5, Synthesis of 11β-(4-N,N-Dimethylaminophenyl)-19-norpregna-4,9,16-triene-3,20-dione.
To a cold (0°C) stirred solution of hydrochloric acid (3 N, 1 mL) was slowly added a solution of 3,3-ethylenedioxy-11β-(4-N,N-dimethylaminophenyl)-5α-hydroxy-19-norpregna-5,16-dien-20-one (23 mg, 0.05 mmol) in tetrahydrofuran (2 mL). After being stirred at room temperature for 2 h, the reaction mixture was poured into a saturated solution of sodium bicarbonate (10 mL) and extracted with methylene chloride (3 × 20 mL). The combined extracts were washed with water (2 ×

20 mL) and brine. Removal of the dried (Na2SO4) solvent in vacuo gave the crude product, which was purified by elution from silica gel (0.5 g using 1% acetone-methylene chloride containing 0.1% Et3N) to yield 12 mg (50%) of 11β-(4-N,N-dimethylaminophenyl)- 19-norpregna-4,9,16-triene-3,20-dione as a foam; IR (CHCl3) 1675 cm-1; 1H NMR (250 MHz, CDCl3) δ 0.66 (s, 3, 18-H), 2.26 (s, 3, 21-H), 2.91 (s, 6, NMe2), 4.28 (m, 1, 11-H), 5.75 (s, 1, 4-H), 6.60 (d, J = 9 Hz, 2, ArH ortho to NMe2), 6.68 (apparent s, 1, 16-H), 7.06 (d, J = 9 Hz, 2, ArH meta to NMe2). Mass spectrum: m/z required for C28H33NO2; 415.2511. Found: 415.2513.
Example 6. Synthesis of 11β-(4-N,N-Dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione.
3,3-Ethylenedioxy-11β-(4-N,N-dimethylaminophenyl- 5α-hydroxy-19-norpregna-9,16-diene-3,20-dione in ethanol solution was reduced with hydrogen in the presence of 5% palladium on charcoal. After one mole of hydrogen per mole of steroid was taken up, the solution was filtered and treated with hydrochloric acid in ethanol as described in Example 1. Evaporation left a residue which was purified by chromatography to yield 11β-(4-N,N-dimethylaminopheny1)-19-norpregna-4,9-diene-3,20-dione.
Example 7. Synthesis of 11β-(4-N,N-Dimethylaminophenyl)-19-norpregna-4,9,17(20)-trien-3-one.
3,3-Ethylenedioxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-9,17(20)-dien-5α-ol was treated with hydrochloric acid in ethanol as described in Example 1 and purified by chromatography to yield 11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9,17(20)-trien-3-

one .
Example 8. Synthesis of 11β-(4-acetylphenyl-19-norpregna-4,9,16-triene-3,20-dione.
By the procedure described in Example 1 for the synthesis of 6α-methyl-11β-(4-N,N-dimethylaminophenyl)- 3,3,20,20-bis(ethylenedioxy)-19-norpregn-g-ene-5α, 17α-diol from 6α-methy1-3,3,20,20-bis(ethylenedioxy)-19-norpregna-5(10),9(11)-dien-17α-ol, but substituting 2-(4-bromomagnesiumphenyl)-2,5,5-trimethyl-1,3-dioxane for p-N,N-dimethylaminophenylmagnesium bromide, 3,3-(ethylenedioxy)estra-5(10),9(11)-dien-17-one was converted to 3,3-ethylenedioxy-5α-hydroxy-11β-[4-(2,5,5-trimethyl-1,3-dioxan-2-yl)phenyl]estr-9-en-17-one. The latter compound was subjected to the procedures of Example 4 for converting 3,3-ethylenedioxy-11β-(4-N,N-dimethylaminophenyl)-5α- hydroxy-9-estren-17-one to 3,3-ethylenedioxy-11β-(4-N,N-dimethylaminophenyl)-5α-hydroxy-19-norpregna-9,16-dien-20-one followed by acid hydrolysis as described in Example 5 to yield 11β-(4-acetylphenyl)-19-norpregna-4,9,16-triene-3,20-dione, m.p. around 194-197°C. Mass spectrum: m/z required for C28H30O3: 414.2195. Found: 414.2189.
Example 9. In Vitro Binding to Receptors The in vitro activity of the subject compounds was determined by measuring the binding affinities (RBA) of these compounds relative to progesterone for the progesterone receptor in the cytosol obtained from estrogen-primed immature rabbit uterus and by measuring the RBA relative to dexamethasone for the glucocorticoid receptor from thymus of adrenalectomized rats. These assays were carried out by the procedures of J.R. Reel et al., Fertility and Sterility, 31, 552 (1979) (progesterone) and G.P. Chrousos et al.,

Endocrinology, 107, 472 (1980) (glucocorticoid). The results are presented in Table 1.

Example 10. In Vivo Antiprogestational Activity
The antiprogestational activity of the compounds was studied after both intrauterine and oral administration. In each case the compound was tested for its ability to inhibit the endometrial response due to subcutaneous administration of progesterone to estrogen-primed immature female rabbits. The methodology used for the intrauterine test has been described by D.A. McGinty et al. See Endocrinology, 24, 829 (1939). For oral administration of test compounds, the method used was analogous to that of Clauberg. See Clauberg, Zentr. Gynakol., 54, 2757 (1930) as modified by McPhail J. Physiol. (London), 83, 145 (1935). The results of the intrauterine tests are given in Table 2. Each active compound was characterized by a dose-related ability to block the progestational effect of simultaneously administered progesterone. When the percent inhibition was plotted versus the log of the dose, linear relationships were obtained. Linear regression analysis permitted calculation of the ED50 and ED90 values (the doses required for 50% and 90% inhibition of the progesterone effect, respectively). The actual dose which gave 90% or more inhibition is also given, although this value is probably less accurate than the calculated values which are based on the dose-response line. Very unexpectedly, these results do not correlate well at all with the in vitro binding studies. Since the intrauterine administration bypasses most of the drug-metabolizing systems of the body, especially the liver, intrinsic activity is expected to correlate reasonably well with binding activity to the receptor, according to currently held hypotheses regarding receptor binding. However

although the 17α-acetoxy compounds bind well and also exhibit potent antiprogestational activity, the Δ-16 compound had even more potent activity even though its RBA was less than one-fifth of the value of the 17α-acetoxy compounds. Even more surprising was the lack of antiprogestational activity of the 16α-ethyl compounds, even though they exhibited the strongest binding to the progesterone receptor.
The 17α-acetoxy compounds also exhibited strong antiprogestational activity when given by the oral route, as is shown in Table 3 for 17α-acetoxy-6α-methyl-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,g-diene-3,20-dione.

TABLE 3
Oral Antiprogestational Activity
(Anti-Clauberg) of 17α-Acetoxy-6α-methyl-11β- (4-N.N-dimethylaminophenyl )-19-nor-pregna-4.9-diene-3.20-dione (15)
Total Oral Total SC McPhail
Dose Dose of Wt of Uterus Index %
Na (mg) Progesterone (mg) (g ± SD) (0-4) Inhibitionb
6 0.0 0.0 1.98 ± 0.40 0 —
6 0.0 0.8 3.06 ± 0.45 3.96 t 0.04 —
6 1.0 0.8 3.25 ± 0.34 3.46 ± 0.12 12.7 ± 3.0
6 5.0 0.8 2.14 ± 0.22 1.92 ± 0.48 51.6 ± 12.2
5 10.0 0.8 2.24 ± 0.27 1.30 ± 0.24 67.2 ± 5.1
a Number of rabbits. b Based on change in HePhail Index.

Example 11. Progestational Activity in Vivo
The 16α-ethyl compounds which showed no antiprogestational activity were examined for progestational activity in the intrauterine assay. In this assay estrogen-primed immature female rabbits are treated by injection of the test compound into the left horn of the uterus while the right horn is left untreated as a control. Each horn is then scored for endometrial proliferation by the McPhail Index. As Table 4 shows, these compounds were potent progestational agents. This is a totally unexpected result, since all examples of prior art known to the inventors show that compounds which bind to the progesterone reeptor and contain an 11β-(4-N,N-dimethylaminophenyl)-substituent exhibit antiprogestational activity. It indicates a possible need for reassessment of the current hypotheses regarding the effect of this substituent on antagonist versus agonist activity. Obviously, numerous modifications and variations of the present invention are possible in light of the above teachings. It is therefore to be understood that within the scope of the present claims, the invention may be practiced otherwise than as specifically described herein.

Claims (19)

Claims

1. An 11β-aryl-19-norprogesterone steroid of the formula:
wherein (i) R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5, wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl, R4 is H, CH3, F or Cl, R6 is H, (CH3)2N, CH3O, CH3CO, CH3S, CH3SO, CH3SO2, and X is O or NOCH3; or
(ii) R1 and R2 taken together are a carbon-carbon bond and R3, R4, R6 and X are as defined above; or
(iii) R1 and R3 taken together are -CH2- or -N=N-CH2-, R2 is H and R4, R6 and X are as defined above; or
(iv) R2 and R3 taken together are =CH2 and R1, R4, R6 and X are as defined above in (i).

2. The norprogesterone of Claim 1 of the formula:
wherein R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, OH, OC(O)CH3, or OC(O)R5, wherein R5 is C2-8 alkyl, C2-8 alkenyl, C2-8 alkynyl or aryl, R2 is H, R3 is H, C1-4 alkyl, C2-4 alkenyl or C2-4 alkynyl, R4 is H, CH3, F or Cl, R6 is H, (CH3)2N, CH3O, CH3CO, CH3S,, CH3SO, CH3SO2, and X is O or NOCH3.

3. The norprogesterone of Claim 2, wherein R6 is N,N-dimethylamino or acetyl.

4. The norprogesterone of Claim 2, wherein R4 is hydrogen or methyl and R1 is acetoxy or C2-8 alkynyl.

5. The norprogesterone of Claim 2, wherein said norprogesterone is 17α-acetoxy-6α-methyl-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 17α-acetoxy-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 16α-ethyl-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 16α-ethyl-6α-methyl-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 17α-ethynyl-11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, 11β-(4-acetylphenyl)-19-norpregna-4,9-diene-3,20-dione, 17α-acetoxy-11β-(4-acetylphenyl)-19-norpregna-4,9-diene-3,20-dione, or 17α-ethynyl-11β-(4-acetylphenyl)-19-norpregna-4,9-diene-3,20-dione.

6. The norprogesterone of Claim 1, of the formula:
wherein R3, R4, R6 and X are as defined in (i).

7. The norprogesterone of Claim 6, wherein R6 is N,N-dimethylamino or acetyl.

8. The norprogesterone of Claim 6, wherein said norprogesterone is 11β-(4-N,N-dimethylaminophenyl)-19-norpregna-4,9,16-triene-3,20-dione or 11β-(4-acetylphenyl)-19-norpregna-4,9,16-triene-3,20-dione.

9. The norprogesterone of Claim 1 having the formula:

wherein R1 and R3 taken together are -CH2- or -N=N- CH2-, R2 is H and R4, R6 and X are as defined in (i).

10. The norprogesterone of Claim 9, wherein R4 is hydrogen or methyl and R6 is dimethylamino or acetyl.

11. The norprogesterone of Claim 1, having the formula:
wherein R1, R4, R6 and X are as defined in (i).

12. The norprogesterone of Claim 11, wherein R1 is acetoxy or C2-8 alkynyl, R4 is hydrogen or methyl and R6 is dimethylamino or acetyl.

13. A method of inducing an anti-glucocorticoid antihormonal response, comprising administering to a human or non-human mammal in need thereof, an antiglucocorticoid effective amount of a norprogesterone of Claim 1, said norprogesterone having a binding affinity for the glucocorticoid receptor and having anti glucocorticoid activity in said human or non-human mammal.

14. The method of Claim 13, wherein said effective amount is a unit dose between 0.1 milligram and 1.0 gram.

15. The method of Claim 13, wherein said human or non-human mammal exhibits Cushing’s syndrome or glaucoma.

16. A method of inducing a progestational hormonal response, comprising administering to a human or non-human mammal in need thereof, a progestional effective amount of a norprogesterone of Claim 1, said norprogesterone having a binding affinity for the progesterone receptor and possessing progestational activity in said human or non-human mammal.

17. The method of Claim 16, wherein said effective amount is a unit dose between 0.1 milligram and 1.0 gram.

18. A method of inducing an anti-progestational response in a human or non-human mammal, comprising administering to a human or non-human mammal in need thereof, an anti-progestational effective amount of a norprogesterone of Claim 1, said norprogesterone having a binding affinity for the progesterone receptor and possessing anti-progestational activity in said human or non-human mammal.

19. The method of Claim 18, wherein said effective amount is a unit dose between 0.1 milligram and 2.0 grams.

AU38506/89A
1988-06-23
1989-06-23
11 beta-substituted progesterone analogs

Expired

AU635211B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US210503

1988-06-23

US07/210,503

US4954490A
(en)

1988-06-23
1988-06-23
11 β-substituted progesterone analogs

Publications (2)

Publication Number
Publication Date

AU3850689A
true

AU3850689A
(en)

1990-01-12

AU635211B2

AU635211B2
(en)

1993-03-18

Family
ID=22783162
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU38506/89A
Expired

AU635211B2
(en)

1988-06-23
1989-06-23
11 beta-substituted progesterone analogs

Country Status (13)

Country
Link

US
(2)

US4954490A
(en)

EP
(1)

EP0422100B1
(en)

JP
(1)

JP2953725B2
(en)

KR
(1)

KR0161975B1
(en)

AT
(1)

ATE149839T1
(en)

AU
(1)

AU635211B2
(en)

CA
(1)

CA1338906C
(en)

DE
(2)

DE68927861T2
(en)

DK
(1)

DK175760B1
(en)

LU
(1)

LU91575I2
(en)

NL
(1)

NL300392I2
(en)

NO
(2)

NO905546L
(en)

WO
(1)

WO1989012448A1
(en)

Families Citing this family (88)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

DE3832303A1
(en)

*

1988-09-20
1990-04-12
Schering Ag

11SS-PHENYL-14SSH STEROIDS

DE59010853D1
(en)

*

1989-08-04
1998-12-03
Schering Ag

11 beta-aryl-gona-4,9-diene-3-one

USRE34578E
(en)

*

1990-05-07
1994-04-05
Lubkin; Virginia
Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application

US5041434A
(en)

*

1991-08-17
1991-08-20
Virginia Lubkin
Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application

DE4042004A1
(en)

*

1990-12-22
1992-06-25
Schering Ag

14 (BETA) -H-, 14- & 15-EN-11 (BETA) -ARYL-4-ESTRENE

US5407928A
(en)

*

1990-08-15
1995-04-18
Schering Aktiengesellschaft
11β-aryl-gona-4,9-dien-3-ones

DE69326836T2
(en)

*

1992-04-21
2000-02-24
Schepens Eye Res Inst

ANDROGEN THERAPY EYE IN SJÖGRENS SYNDROME

US5536725A
(en)

*

1993-08-25
1996-07-16
Fmc Corporation
Insecticidal substituted-2,4-diamino-5,6,7,8-tetrahydroquinazolines

US5639598A
(en)

*

1994-05-19
1997-06-17
The Trustees Of The University Of Pennsylvania
Method and kit for identification of antiviral agents capable of abrogating HIV Vpr-Rip-1 binding interactions

ZA953976B
(en)

*

1994-05-19
1996-01-19
Akzo Nobel Nv
11,21-bisphenyl-19-norpregnane derivatives

US5780220A
(en)

*

1994-05-19
1998-07-14
Trustees Of The University Of Pennsylvania
Methods and compositions for inhibiting HIV replication

US5929262A
(en)

*

1995-03-30
1999-07-27
The United States Of America As Represented By The Department Of Health And Human Services
Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates

CA2668824A1
(en)

*

1996-05-01
1997-11-06
The Government Of The United States Of America, Represented By The Secre Tary Of The Department Of Health And Human Services
21-substituted progesterone derivatives as new antiprogestational agents

US6900193B1
(en)

*

1996-05-01
2005-05-31
The United States Of America As Represented By The Department Of Health And Human Services
Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents

WO1998005679A2
(en)

*

1996-08-05
1998-02-12
Duke University
Mixed agonists of the progesterone receptor and assays therefor

US6090798A
(en)

*

1997-12-19
2000-07-18
Alcon Laboratories, Inc.
Treatment of GLC1A glaucoma with glucocorticoid antagonists

US6020328A
(en)

*

1998-03-06
2000-02-01
Research Triangle Institute
20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties

US6262042B1
(en)

1998-05-29
2001-07-17
Research Triangle Institute
17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties

US5962444A
(en)

*

1998-05-29
1999-10-05
Research Triangle Institute
17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties

US6172052B1
(en)

*

1998-12-04
2001-01-09
Research Triangle Institute
17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties

US6740645B1
(en)

1999-09-03
2004-05-25
Research Triangle Institute
17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties

DK1265911T3
(en)

*

2000-03-17
2008-09-29
Us Gov Health & Human Serv

17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnedienedione as antiprogestational agents

EP1363876B1
(en)

*

2001-02-14
2009-07-29
Karo Bio Ab
Glucocorticoid receptor modulators

ES2212912B1
(en)

2003-01-22
2005-10-01
Crystal Pharma, S.A.

PROCEDURE FOR OBTAINING 17ALFA-ACETOXI-11BETA- (4-N, N-DIMETHYLAMINEPHENYL) -19-NORPREGNA-4,9-DIEN-3,20-DIONA.

JP2006519255A
(en)

*

2003-02-28
2006-08-24
アメリカ合衆国

Process for producing 17α-acetoxy-11β- (4-N, N-dimethylaminophenyl) -19-norpregna-4,9-diene-3,20-dione, its intermediate and process for producing such an intermediate

US20060247452A1
(en)

*

2004-01-21
2006-11-02
Guisasola Luis Octavio S
Method for obtaining 17sg(a)-acetoxy-11$g(b)-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione

US8865200B2
(en)

*

2004-07-09
2014-10-21
Laboratoire Hra Pharma
Sustained release compositions containing progesterone receptor modulators

EP1862468A1
(en)

*

2006-06-02
2007-12-05
Bayer Schering Pharma Aktiengesellschaft
Crystalline 11beta-(4-acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-one

HU227112B1
(en)

*

2006-06-14
2010-07-28
Richter Gedeon Nyrt
Industrial process for the synthesis of 17alpha-acetoxy-11betha-[4-(n,n-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione and the new intermediates of the process

WO2008129396A2
(en)

*

2007-04-20
2008-10-30
Preglem S.A.
Progesterone antagonist and selective progesterone modulator in the treatment of uterine bleeding

HU228636B1
(en)

*

2007-06-27
2013-04-29
Richter Gedeon Nyrt
Industrial method for the synthesis of 17-acetoxy-11betha-4[-(dimethylamino)-phenyl]-21-methoxy-19-norpregna-4,9-dien-3,20-dione and the key intermediates of the process

EP2532350A1
(en)

2007-10-17
2012-12-12
Laboratoire HRA Pharma
Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing’s syndrome

US8299050B2
(en)

2008-01-29
2012-10-30
Laboratoire Hra-Pharma
Method for treating uterine fibroids

US8512745B2
(en)

*

2008-12-08
2013-08-20
Laboratoire Hra Pharma
Ulipristal acetate tablets

AU2010237120B8
(en)

2009-04-14
2015-11-26
Laboratoire Hra-Pharma
Method for on-demand contraception

DE102009034362A1
(en)

2009-07-20
2011-01-27
Bayer Schering Pharma Aktiengesellschaft

17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases

DE102009034366A1
(en)

2009-07-20
2011-01-27
Bayer Schering Pharma Aktiengesellschaft

17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-methyleneoxyalkylene aryl derivatives, process for their preparation and their use for the treatment of diseases

DE102009034368A1
(en)

2009-07-20
2011-01-27
Bayer Schering Pharma Aktiengesellschaft

17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases

DE102009034367A1
(en)

2009-07-20
2011-01-27
Bayer Schering Pharma Aktiengesellschaft

17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-benzylidene derivatives, process for their preparation and their use for the treatment of diseases

DE102009034526A1
(en)

2009-07-21
2011-02-10
Bayer Schering Pharma Aktiengesellschaft

17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-ethynylphenyl derivatives, process for their preparation and their use for the treatment of diseases

DE102009034525A1
(en)

2009-07-21
2011-01-27
Bayer Schering Pharma Aktiengesellschaft

17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases

US8426392B2
(en)

2009-12-09
2013-04-23
Laboratoire Hra-Pharma
Method for providing emergency contraception

WO2011091890A1
(en)

2010-02-01
2011-08-04
Laboratoire Hra-Pharma
A method for post coital contraception in overweight for obese female subjects using ulipristal acetate

WO2011091892A1
(en)

2010-02-01
2011-08-04
Ulmann Andre
A method for late post coital contraception using ulipristal acetate

DE102010007719A1
(en)

2010-02-10
2011-08-11
Bayer Schering Pharma Aktiengesellschaft, 13353

Progesterone receptor antagonist

DE102010007722A1
(en)

2010-02-10
2011-08-11
Bayer Schering Pharma Aktiengesellschaft, 13353

Progesterone receptor antagonist

CN102906103A
(en)

*

2010-03-22
2013-01-30
利普生物药剂公司
Compositions and methods for non-toxic delivery of antiprogestins

WO2011150209A1
(en)

2010-05-26
2011-12-01
Corcept Therapeutics, Inc.
Treatment of muscular dystrophy

CN102372760A
(en)

*

2010-08-12
2012-03-14
杭州容立医药科技有限公司
Synthesis method of progesterone receptor regulating agent ulipristal

UA113283C2
(en)

*

2010-12-23
2017-01-10

19-NORSTEROIDS AND THEIR APPLICATIONS FOR THE TREATMENT OF PROGESTERON-STAINLESS STATES

EP2471537A1
(en)

2010-12-30
2012-07-04
PregLem S.A.
Treatment of pain associated with dislocation of basal endometrium

CN102516345B
(en)

2011-11-01
2014-11-26
上海优拓医药科技有限公司
Preparation method of ulipristal acetate and key intermediate thereof

EP2545922A1
(en)

2011-07-12
2013-01-16
PregLem S.A.
Treatment of excessive menstrual bleeding associated with uterine fibroids

CN102344478B
(en)

*

2011-07-22
2013-08-07
上海希迈医药科技有限公司
Crystal of 17 alpha-acetoxyl group-11 beta-(4-N, N-dimethylamino phenyl)-19-norpregna-4, 9- diene-3, 20- ketone and preparation method thereof

CN102321141B
(en)

*

2011-07-22
2013-05-15
上海希迈医药科技有限公司
Amorphous substance of 17alpha-acetoxy-11beta-(4-N,N-dimethylaminophenyl)-19-norpregn-4,9-diene-3,20-diketone and preparation method thereof

CN104628806A
(en)

*

2012-01-19
2015-05-20
华润紫竹药业有限公司
Steroid compound and preparation method and application thereof

CN106046099B
(en)

*

2012-01-19
2018-03-16
华润紫竹药业有限公司
Steroidal compounds and its production and use

FR2987271B1
(en)

2012-02-28
2017-08-18
Hra Pharma Lab

COMBINATION OF SELECTIVE PROGESTERONE RECEPTOR MODULATORS AND NON-STEROID ANTI-INFLAMMATORY DRUGS

EP2641602A1
(en)

2012-03-23
2013-09-25
PregLem S.A.
Method for treating gynecological diseases

CN102675395B
(en)

*

2012-04-17
2014-04-30
常州市第四制药厂有限公司
Polycrystal forms of ulipristal acetate and preparation method thereof

KR20150039130A
(en)

2012-05-25
2015-04-09
라보라토이레 에이치알에이 파르마
Ulipristal acetate for prevention and treatment of breast tumors

KR102127348B1
(en)

2012-05-31
2020-06-29
앨러간 파마슈티컬스 인터내셔널 리미티드
Formulations and methods for vaginal delivery of antiprogestins

CN102702296B
(en)

*

2012-06-19
2014-09-03
山东诚创医药技术开发有限公司
Preparation method of cyclo-3,20-bi(1, 2-ethidene acetal)-17alpha-hydroxyl-17beta-acetyl-estra-5(10),9(11)-diene-3-ketone

KR20150063486A
(en)

2012-09-28
2015-06-09
아스카 세이야쿠 가부시키가이샤
Crystalline polymorphic form of ulipristal acetate

JP6200493B2
(en)

2012-09-28
2017-09-20
あすか製薬株式会社

Amorphous uripristal acetate

WO2014050107A1
(en)

2012-09-28
2014-04-03
Aska Pharmaceutical Co., Ltd.
Crystalline polymorphic form of ulipristal acetate

WO2014060888A1
(en)

2012-10-18
2014-04-24
Lupin Limited
Novel process and intermediate for preparation of ulipristal

CN103772468B
(en)

*

2012-10-19
2017-04-05
华润紫竹药业有限公司
The preparation method and purposes of acetic acid spy’s plast ketone and its intermediate

AU2013338305B2
(en)

2012-11-02
2018-06-07
Allergan pharmaceuticals International Ltd.
Methods and compositions for treating progesterone-dependent conditions

FR2997627B1
(en)

*

2012-11-08
2015-01-16
Hra Pharma Lab

CO-MICRONIZATION PRODUCT COMPRISING ULIPRISTAL ACETATE

FR2997628B1
(en)

2012-11-08
2015-01-16
Hra Pharma Lab

CO-MICRONIZATION PRODUCT COMPRISING A SELECTIVE MODULATOR OF PROGESTERONE RECEPTORS

FR2999081B1
(en)

2012-12-06
2015-02-27
Hra Pharma Lab

SOLID DISPERSION OF A SELECTIVE PROGESTERONE RECEPTOR MODULATOR

CN103073612B
(en)

*

2013-02-04
2015-11-04
山东大学
The preparation method of CDB-2914 key intermediate

JP2016516764A
(en)

2013-04-10
2016-06-09
プレグレム ソシエテ アノニム

Progesterone receptor modulator for the treatment of uterine fibroids

HU230319B1
(en)

*

2013-10-01
2016-01-28
Richter Gedeon Nyrt.
Industrial process for producing steroid derivatives

EP3265127A4
(en)

2015-03-02
2018-08-15
Corcept Therapeutics, Inc.
Use of glucocorticoid receptor antagonist and somatostatin analogues to treat acth-secreting tumors

WO2016160969A1
(en)

2015-03-30
2016-10-06
Corcept Therapeutics, Inc.
Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency

US9829495B2
(en)

2015-08-13
2017-11-28
Corcept Therapeutics, Inc.
Method for differentially diagnosing ACTH-dependent Cushing’s syndrome

AU2017210156B2
(en)

2016-01-19
2021-10-28
Corcept Therapeutics, Inc.
Differential diagnosis of Ectopic Cushing’s Syndrome

CN105669810B
(en)

*

2016-02-19
2017-05-10
常州市第四制药厂有限公司
Impurity of ulipristal acetate and preparation and detecting method of impurity

FR3060389B1
(en)

2016-12-20
2019-05-31
Laboratoire Hra-Pharma

ENROBE COMPRISING COMPRISING ULIPRISTAL ACETATE OR ONE OF ITS METABOLITES

WO2017216637A2
(en)

2017-08-04
2017-12-21
Alvogen Malta Operations (Row) Ltd
Tablet form including ulipristal acetate and the methods for its preparation

CN109053846B
(en)

*

2018-08-14
2020-01-07
台州仙琚药业有限公司
Method for preparing ulipristal bisketal acetate

US20220288091A1
(en)

*

2019-03-18
2022-09-15
Lynnette K. NIEMAN
Method for Improving Insulin Sensitivity

EP3895692A1
(en)

2020-04-15
2021-10-20
LTS Lohmann Therapie-Systeme AG
Oral thin film with smooth fused film

EP3895691A1
(en)

2020-04-15
2021-10-20
LTS Lohmann Therapie-Systeme AG
Ulipristal acetate otf

CA3205462A1
(en)

2020-12-18
2022-06-23
Instil Bio (Uk) Limited
Processing of tumor infiltrating lymphocytes

EP4151204A1
(en)

2021-09-17
2023-03-22
LTS Lohmann Therapie-Systeme AG
Rapidly disintegrating oral thin films/foams with high active agent loading based on a mixture of polyvinyl alcohols having different molecular weights

Family Cites Families (6)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

FR2377418A1
(en)

*

1977-01-13
1978-08-11
Roussel Uclaf

NEW 4,9-DIENIC 11B-SUBSTITUTE STEROID DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICINAL PRODUCTS

ZA8231B
(en)

*

1981-01-09
1982-11-24
Roussel Uclaf
New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained

FR2522328B1
(en)

*

1982-03-01
1986-02-14
Roussel Uclaf

NEW PRODUCTS DERIVED FROM THE STRUCTURE 3-CETO 4,9 19-NOR STEROIDS, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS

ES8502612A1
(en)

*

1983-06-15
1985-02-01
Schering Ag
13-Alpha-alkyl gonanes, their preparation and pharmaceutical compositions containing them.

FR2586021B1
(en)

*

1985-08-09
1988-10-14
Roussel Uclaf

NEW PRODUCTS DERIVED FROM THE STRUCTURE 5A-OH D 9 (10) 19-NOR STEROIDS

IE60780B1
(en)

*

1987-01-23
1994-08-10
Akzo Nv
New 11-aryl steroid derivatives

1988

1988-06-23
US
US07/210,503
patent/US4954490A/en
not_active
Expired – Lifetime

1989

1989-06-22
CA
CA000603686A
patent/CA1338906C/en
not_active
Expired – Lifetime

1989-06-23
DE
DE68927861T
patent/DE68927861T2/en
not_active
Expired – Lifetime

1989-06-23
WO
PCT/US1989/002706
patent/WO1989012448A1/en
active
IP Right Grant

1989-06-23
DE
DE122009000031C
patent/DE122009000031I2/en
active
Active

1989-06-23
AU
AU38506/89A
patent/AU635211B2/en
not_active
Expired

1989-06-23
JP
JP1507392A
patent/JP2953725B2/en
not_active
Expired – Fee Related

1989-06-23
EP
EP89907924A
patent/EP0422100B1/en
not_active
Expired – Lifetime

1989-06-23
AT
AT89907924T
patent/ATE149839T1/en
active

1989-06-23
KR
KR1019900700406A
patent/KR0161975B1/en
not_active
IP Right Cessation

1990

1990-04-03
US
US07/504,129
patent/US5073548A/en
not_active
Expired – Lifetime

1990-12-21
DK
DK199003053A
patent/DK175760B1/en
active
Protection Beyond IP Right Term

1990-12-21
NO
NO90905546A
patent/NO905546L/en
not_active
IP Right Cessation

2009

2009-06-03
LU
LU91575C
patent/LU91575I2/en
unknown

2009-06-11
NL
NL300392C
patent/NL300392I2/en
unknown

2009-06-22
NO
NO2009014C
patent/NO2009014I2/en
unknown

Also Published As

Publication number
Publication date

DE122009000031I2
(en)

2011-06-16

DK175760B1
(en)

2005-02-14

DE68927861T2
(en)

1997-10-16

DE122009000031I1
(en)

2009-11-05

NL300392I1
(en)

2009-08-03

EP0422100A4
(en)

1994-04-27

US5073548A
(en)

1991-12-17

NO905546D0
(en)

1990-12-21

US4954490A
(en)

1990-09-04

DE68927861D1
(en)

1997-04-17

JPH03505582A
(en)

1991-12-05

LU91575I2
(en)

2009-08-03

NO178264C
(en)

1996-02-21

DK305390D0
(en)

1990-12-21

WO1989012448A1
(en)

1989-12-28

NO2009014I2
(en)

2009-12-28

KR0161975B1
(en)

1998-11-16

ATE149839T1
(en)

1997-03-15

NO178264B
(en)

1995-11-13

NL300392I2
(en)

2009-10-01

NO905546L
(en)

1990-12-21

EP0422100A1
(en)

1991-04-17

CA1338906C
(en)

1997-02-11

NO2009014I1
(en)

2009-07-06

JP2953725B2
(en)

1999-09-27

DK305390A
(en)

1990-12-21

KR900701820A
(en)

1990-12-04

AU635211B2
(en)

1993-03-18

EP0422100B1
(en)

1997-03-12

Similar Documents

Publication
Publication Date
Title

EP0422100B1
(en)

1997-03-12

11 beta-substituted progesterone analogs

US4774236A
(en)

1988-09-27

17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them

US7759330B2
(en)

2010-07-20

21-substituted progesterone derivatives as new antiprogestational agents

CA1289944C
(en)

1991-10-01

11 .beta.-(4-ISOPREPENYLPHENYL)ESTRA-4,9-DIENES, THEIR PRODUCTION, AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME

US4447424A
(en)

1984-05-08

Steroid derivatives

US6900193B1
(en)

2005-05-31

Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents

US4861763A
(en)

1989-08-29

17 α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and their progestational use

EP2348030B1
(en)

2015-05-06

17-Alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as antiprogestational agents

US5292878A
(en)

1994-03-08

17-spirofuran-3'-ylidene steroids

IE63483B1
(en)

1995-05-03

New 19-nor steroids having in position 11beta a carbonated chain containing an amide or carbamate function, their preparation process and the intermediates of this process, their use as medicaments and the pharmaceutical compositions containing them

US6740645B1
(en)

2004-05-25

17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties

WO2000034306A1
(en)

2000-06-15

17β-ACYL-17α-PROPYNYL-11β-ARYLSTEROIDS AND THEIR DERIVATIVES HAVING AGONIST OR ANTAGONIST HORMONAL PROPERTIES

KR0160280B1
(en)

1998-11-16

19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors

HU208154B
(en)

1993-08-30

Process for producing new omega-phenylaminoalkanoic acid derivatives and pharmaceutical compositions comprising same as active ingredient

US5707982A
(en)

1998-01-13

19-nor-steroids

Download PDF in English